Catheter Precision

Catheter Precision EBITDA per Share

The EBITDA per Share of Catheter Precision (VTAK) as of Oct 21, 2026 is -0.02 USD. In the previous year, EBITDA per Share was -1.43 USD — a change of -98.75% (higher).

EBITDA per Share

-0.02USD

YoY

-98.75%

Last updated:

EBITDA per Share of Catheter Precision is 2025 -0.02 USD. EBITDA per Share of Catheter Precision was 2024 -1.43 USD. It decreases by -98.75% higher compared to the previous year.

The Catheter Precision EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-3,054.90 USD
Jan 1, 2019
-5,345.37 USD
Jan 1, 2020
-622.78 USD
Jan 1, 2021
-217.11 USD
Jan 1, 2022
-2,365.00 USD
Jan 1, 2023
-10.83 USD
Jan 1, 2024
-1.43 USD
Jan 1, 2025
-0.02 USD
The Catheter Precision EBITDA per Share history
YEAREBITDA per ShareYoY
-0.02USD-98.75%
-1.43USD-86.84%
-10.83USD-99.54%
-2,365.00USD+989.33%
-217.11USD-65.14%
-622.78USD-88.35%
-5,345.37USD+74.98%
-3,054.90USD+66.85%
-1,830.93USD+120.70 M%
-0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Catheter Precision Stock analysis

What does Catheter Precision do? Ra Medical Systems, Inc. generates revenue through the sale of its electrophysiology products Amigo, VIVO, and LockeT to hospitals, physicians, and healthcare providers. The company's Amigo remote catheter system, featuring an open architecture design, allows for versatile use across multiple catheter procedures. VIVO, a non-invasive 3D imaging system, helps physicians identify arrhythmia origins pre-procedure, improving workflow efficiency. LockeT, a suture retention device, supports surgical procedures. These products target cardiac arrhythmia treatment, serving medical institutions and healthcare professionals seeking advanced solutions for patient care. The firm collaborates with physicians to develop and advance its electrophysiology technologies, focusing on improving cardiac arrhythmia procedures. Its product portfolio addresses the need for streamlined workflows and reduced procedure times in electrophysiology settings. Hospitals and physicians purchase these solutions to enhance patient outcomes and operational efficiency in treating vascular immune-mediated inflammatory diseases. The company's commercialization strategy centers on delivering innovative technologies that meet evolving clinical demands in cardiology. Ra Medical Systems, Inc. is engaged in providing new solutions to the market for cardiac arrhythmia treatment, emphasizing technology development for electrophysiology procedures. Its products are designed to improve patient lives through advanced catheter-based systems and imaging solutions. The company's focus on physician collaboration ensures that its offerings align with clinical needs, driving adoption among healthcare providers specializing in cardiac care. Catheter Precision is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Catheter Precision stock

EBITDA per Share of Catheter Precision is -0.02 USD in 2025.

EBITDA per Share of Catheter Precision changed from -1.43 USD to -0.02 USD, representing a -98.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Catheter Precision since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Catheter Precision

All Key Metrics — Catheter Precision